There was a notable sale of shares of Exact Sciences by an insider today, as disclosed in a form 4 document filed with the SEC. One insider -- G Bradley...
G Bradley Cole, General Manager - Diagnostics, executed a sale of 28,016 shares of Exact Sciences (EXAS) on Nov 21, 2019, for $2,251,926. After the Form 4...
Exact Sciences' (EXAS) average rating among analysts is a buy, with an average price target of $126. Price: 80.87, Change: +1.63, Percent Change: +2.06 ...
Exact Sciences (EXAS), a provider of cancer screening and diagnostic tests, has completed the acquisition of Genomic Health (GHDX), according to a release...
| Address | 441 Charmany Drive Madison, Wisconsin 53719 |
| Phone | +1.608.284.5700 |
| Number of Employees | 1,977 |
| Recent SEC Filing | 11/27/2019 8-K |
| Chairman, President & Chief Executive Officer | Kevin T. Conroy |
| Senior Vice President-Operations | Ana Hooker |
| Chief Financial Officer | Jeffrey T. Elliott |
| Co-Chief Medical Officer & Head-Medical Affairs | Barry M. Berger |
| Price Open | $85.30 |
| Previous Close | $85.30 |
| 52 Week Range | $53.06 - 123.99 |
| Market Capitalization | $11.1 B |
| Shares Outstanding | 129.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/20/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.71 |
| Beta vs. S&P 500 | N/A |
| Revenue | $454.5 M |
| Net Profit Margin | -29.83% |
| Return on Equity | -29.06% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
